You are here

Injectable Foam to Staunch Bleeding is Breakthrough Therapy

Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma

Life Foam™, an expanding, internal-use injectable hemostat, designed by gel-e Inc., has received a breakthrough status designation from the FDA.

Life Foam provides rapid, temporary control of bleeding from non-compressible abdominal wounds that do not lend themselves to tourniquet application during trauma and battlefield conditions. The product is designed to save the lives of those injured in battle, or who are victims of traumatic accidents or terrorist attacks.

Trauma from accidents is the third leading cause of death in the U.S. after heart disease and cancer. Approximately 85% of all hemorrhage-related deaths arise from non-compressible internal bleeding––intracavitary (e.g., abdominal) bleeding that is not accessible to direct pressure and cannot be controlled by typical methods such as gauze or a tourniquet.

When it is delivered into the abdominal cavity, Life Foam expands dramatically, seeking out the bleeding source in the patient for quick and efficient stabilization. This enables the injured person to be safely transported to a trained trauma surgeon, who can repair the damage in a controlled surgical environment.

The foam is currently in preclinical development for treating patients who have been injured in battlefield conditions or where life-threatening internal bleeding occurs in a location away from immediate urgent care.

Source: BioSpace, June 18, 2019

Recent Headlines

The answer may offer a potential treatment for the disease
Drug resistance in HIV patients has nearly tripled since 2001
Drug resistance in HIV patients has nearly tripled since 2001
New drug addresses bacterial resistance to standard therapy
Hovering flights lower packages by cable and winch
Ziextenzo helps lower the incidence of febrile neutropenia
The number of those with an annual drug spend of $250K or more has increased by 60%
Grading manufacturers would give high-quality, reliable makers a boost, says federal panel
Sharpless is heading back to NCI